Tag Archive for: financing round

Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials

PRESS RELEASE | Basel, Switzerland, July 15, 2020

Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective May 1 to advance its lead molecule into clinical development. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform.

Read more

Versameb raises CHF 6.4 million in Seed C round and strengthens the team

PRESS RELEASE | Basel, Switzerland, October 17, 2019

Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a CHF 6.4 million Seed C financing round, bringing the total capital raised to date to CHF 11.8 million. Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.

Read more

Versameb raises CHF 5.3 million for the development of mRNA therapies in regenerative medicine

PRESS RELEASE | Basel, December 18, 2018

Versameb AG, a Swiss biopharmaceutical company, announced today the successful closing of a Seed B financing round, bringing the total capital raised to date to CHF 5.3 millions. Versameb AG is developing a technology platform for transformative therapies, focusing on regenerative medicine through the local application of messenger ribonucleic acid (mRNA).

Read more